"This is interesting: Claude is already achieving roughly twice the protein-design hit rate of conventional human-led workflows. 27% hit rate in autonomous protein binder design, roughly twice the typical 10–15% rate reported in the field. Working from one expert-written protocol, Claude..."
> Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per https://t.co/CGCNTNaKBq > > — Anthropic
Source: https://x.com/AnthropicAI/status/2089842387845804246
> This is interesting: Claude is already achieving roughly twice the protein-design hit rate of conventional human-led workflows. 27% hit rate in autonomous protein binder design, roughly twice the typical 10–15% rate reported in the field. > > Working from one expert-written protocol, Claude designed binders against 14 of 15 measurable targets. Independent labs confirmed that 354 of 1,320 designs bound successfully. > > Depending on the setup, Claude’s hit rate ranged from 22.6% to 35.1%. Its top-ranked design bound in 49% of campaigns. > > This is not yet fully autonomous drug research, but it is another important building block in that direction. > > > — Chubby
Source: https://x.com/kimmonismus/status/2089852014331117694